Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Plasma Cell Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00008359
What this trial is testing

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT07109323
What this trial is testing

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Who this might be right for
Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High RiskPrimary Refractory+4 more
Institute of Hematology & Blood Diseases Hospital, China 50
Testing effectiveness (Phase 2)Study completedNCT02331368
What this trial is testing

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Michigan Rogel Cancer Center 32
Testing effectiveness (Phase 2)Ended earlyNCT00963872
What this trial is testing

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma+1 more
Masonic Cancer Center, University of Minnesota 31
Testing effectiveness (Phase 2)Study completedNCT04478123
What this trial is testing

Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

Who this might be right for
Multiple MyelomaHodgkin LymphomaNon-Hodgkin Lymphoma+1 more
Memorial Sloan Kettering Cancer Center 62
Testing effectiveness (Phase 2)Study completedNCT00064311
What this trial is testing

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
National Institutes of Health Clinical Center (CC)
Testing effectiveness (Phase 2)Looking for participantsNCT06246162
What this trial is testing

Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma

Who this might be right for
Multiple Myeloma
Affiliated Hospital of Nantong University 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04270409
What this trial is testing

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma
Sanofi 337
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07789522
What this trial is testing

Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China 15
Testing effectiveness (Phase 2)Ended earlyNCT00337506
What this trial is testing

Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nantes University Hospital 50
Large-scale testing (Phase 3)Study completedNCT02939287
What this trial is testing

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Who this might be right for
NauseaVomiting
Rush University Medical Center 52
Early research (Phase 1)Ended earlyNCT00052884
What this trial is testing

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Who this might be right for
Drug/Agent Toxicity by Tissue/OrganMultiple Myeloma and Plasma Cell Neoplasm
Eastern Cooperative Oncology Group 8
Early research (Phase 1)Looking for participantsNCT05055063
What this trial is testing

With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT05908409
What this trial is testing

IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Who this might be right for
Multiple Myeloma (MM)Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDouble Hit Lymphoma+3 more
IDP Discovery Pharma S.L. 37
Testing effectiveness (Phase 2)Study completedNCT00003269
What this trial is testing

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

Who this might be right for
Breast CancerDrug/Agent Toxicity by Tissue/OrganLung Cancer+3 more
Scripps Health 20
Early research (Phase 1)Study completedNCT02918331
What this trial is testing

JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 7
Large-scale testing (Phase 3)Looking for participantsNCT07393282
What this trial is testing

Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Who this might be right for
High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals 270
Testing effectiveness (Phase 2)Active Not RecruitingNCT03756896
What this trial is testing

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma
Emory University 29
Testing effectiveness (Phase 2)WithdrawnNCT00112879
What this trial is testing

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Who this might be right for
Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma+1 more
The Cleveland Clinic
Large-scale testing (Phase 3)Study completedNCT00480363
What this trial is testing

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 120
Next Page